Kelowna, B.C., August 6, 2019 – Valens GroWorks Corp. (TSXV: VGW) (OTC: VGWCF) (the “Company” or “Valens”), a vertically integrated provider of industry-leading extraction products and services; including a diverse suite of extraction methodologies, next-generation cannabinoid delivery formats and an ISO 17025 accredited analytical lab, is pleased to announce it has expanded its operational footprint with the opening of offices in Toronto as it gears up for geographic expansion.

Downtown Toronto Offices

Opening offices in downtown Toronto is a key next step in Valens’ evolution as it looks to leverage its state of the art operations, technical expertise and advanced product portfolio in new, high-value markets, globally.  A Toronto office improves the Company’s ability to realize on a number of international opportunities, increases its ability to attract and retain top talent, coordinate global operations, manage international customer relationships and expand access to the institutional investment community.

“Toronto will be a hub for international growth and business development and complement the incredible operational platform we have built in Kelowna. This is an exciting milestone as we continue to advance our business and accelerate our growth into new regions. Having a base in Toronto also increases our access to the institutional investment community”  – Tyler Robson, CEO of Valens.

 

About Valens GroWorks

Valens GroWorks Corp. (TSXV:VGW) (OTC:VGWCF) is a multi-licensed, vertically-integrated cannabis company focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white-label product development.  Valens is the largest third-party extraction Company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant.  Additionally, our subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science.  For more information, please visit the Valens GroWorks website.  The Company’s investor deck can be found specifically at https://thevalenscompany.com.au/investors/

 

For further information, please contact:

Everett Knight
Email: e.knight@dev-valens-australia.pantheonsite.io
U.S. / Europe Investors

KCSA Strategic Communications
Phil Carlson / Elizabeth Barker
VGW@kcsa.com
212.896.1233 / 212.896.1203

Media
KCSA Strategic Communications
Anne Donohoe
adonohoe@kcsa.com
212.896.1265

 

Notice regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The TSX Venture or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.